CA125、CA19-9、癌胚抗原（CEA）、CA72-4和组织多肽抗原（TPA）在卵巢交界性肿瘤中的临床价值

Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.

作者信息

Tamakoshi K, Kikkawa F, Shibata K, Tomoda K, Obata N H, Wakahara F, Tokuhashi Y, Ishikawa H, Kawai M, Tomoda Y

机构信息

Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.

出版信息

Gynecol Oncol. 1996 Jul;62(1):67-72. doi: 10.1006/gyno.1996.0191.

DOI:10.1006/gyno.1996.0191

PMID:8690294

Abstract

Five tumor markers were analyzed clinically in 101 patients with borderline ovarian tumors who were treated by the Tokai Ovarian Tumor Study Group, an association comprising Nagoya University and its affiliated hospital, between January 1986 and December 1994. The positive rate of CA125 was 68.2% in serous tumor and 51.9% in mucinous tumor. The positive rate of CA19-9 was 51.5% in serous tumor and 44.7% in mucinous tumor. The positive rates and mean serum levels of CA125 in serous and mucinous tumor by stage had rising tendencies with an increase in each stage. The mean serum levels of CA19-9 in serous and mucinous tumor by stage had rising tendencies with an increase in each stage. CA125 and CA19-9 were useful for screening of borderline ovarian tumors. The positive rates of CEA and TPA in mucinous tumor were 32.5 and 27.3%, respectively, although none of the patients with serous tumor were positive in CEA and TPA. The positive rates and mean serum levels of CEA in mucinous tumor by stage had rising tendencies with an increase in each stage. The positive rate of CA72-4 was significantly lower than that of CA125 (P < 0.05).

摘要

1986年1月至1994年12月期间，东海卵巢肿瘤研究组（由名古屋大学及其附属医院组成的协会）对101例卵巢交界性肿瘤患者进行了5种肿瘤标志物的临床分析。CA125在浆液性肿瘤中的阳性率为68.2%，在黏液性肿瘤中的阳性率为51.9%。CA19-9在浆液性肿瘤中的阳性率为51.5%，在黏液性肿瘤中的阳性率为44.7%。浆液性和黏液性肿瘤中CA125的阳性率和血清平均水平随分期增加呈上升趋势。浆液性和黏液性肿瘤中CA19-9的血清平均水平随分期增加呈上升趋势。CA125和CA19-9对卵巢交界性肿瘤的筛查有帮助。黏液性肿瘤中CEA和TPA的阳性率分别为32.5%和27.3%，而浆液性肿瘤患者中CEA和TPA均无阳性。黏液性肿瘤中CEA的阳性率和血清平均水平随分期增加呈上升趋势。CA72-4的阳性率显著低于CA125（P<0.05）。